Line of Sight
PET and MRI imaging techniques are beginning to enter onto the radar of the pharma industry.
Kevin Cox from Imanova is sure they will become key tools in early-stage drug development
decision-making, but warns that preconceptions that imaging is costly must be tackled first.
Kevin Cox, Imanova (March 2014)
Keywords: Imaging biomarkers, Positron emission tomography, Magnetic resonance imaging, Fast-to-fail strategies, Multimodal approach